Buprenorphine/Naloxone

Introduction Overview

Generic Name

buprenorphine/naloxone

Brand Name

Cassipa, Suboxone, Zubsolv

Dosage Form

sublingual tablets, sublingual film, buccal film

Drug Class

narcotic analgesic combinations

Pharmacokinetics

Absorption

Buprenorphine/naloxone is administered primarily via sublingual tablets, sublingual film, or buccal film, allowing the active drugs to be absorbed directly through the mucous membranes of the mouth, bypassing first-pass hepatic metabolism and improving bioavailability. Buprenorphine has an oral bioavailability of approximately 30% to 50% when administered sublingually or buccally, whereas naloxone exhibits poor systemic absorption through these routes, which is intentional to reduce abuse potential. Peak plasma concentrations of buprenorphine are generally observed within 90 to 180 minutes after sublingual dosing. Factors influencing absorption include saliva pH, mucosal integrity, and dose form presentation (film or tablet).

Distribution

Buprenorphine is highly lipophilic, leading to extensive tissue distribution, with an apparent volume of distribution ranging from 2 to 8 L/kg. It is approximately 96% bound to plasma proteins, mainly albumin and alpha- and beta-globulins. Naloxone has a smaller volume of distribution with moderate plasma protein binding (~45%). Both drugs cross the placenta and can be detected in breast milk. Buprenorphine’s high lipid solubility allows it to cross the blood-brain barrier, exerting central opioid effects, while naloxone’s limited systemic absorption when administered sublingually limits central activity to minimize antagonist effects during compliant use.

Metabolism

Buprenorphine is extensively metabolized in the liver primarily via cytochrome P450 3A4 (CYP3A4) enzymes to norbuprenorphine, an active metabolite with opioid agonist properties but limited CNS penetration. Additional minor metabolism occurs via CYP2C8 isoenzymes. Naloxone is subject to first-pass hepatic metabolism mainly by UGT enzymes, leading to rapid conversion to naloxone-3-glucuronide, an inactive metabolite. The combination formulation’s sublingual and buccal routes minimize naloxone’s systemic exposure and metabolism under normal use, but naloxone is bioavailable and active if injected or misused. Potential interactions with CYP3A4 inhibitors or inducers can significantly impact buprenorphine plasma levels and clinical effect.

Elimination

Buprenorphine and its metabolites are excreted primarily via biliary/fecal routes, with approximately 70% eliminated through feces and 30% via the urine. The terminal half-life of buprenorphine ranges from 24 to 42 hours, supporting once-daily dosing in opioid maintenance therapy. Naloxone has a plasma elimination half-life of about 1 to 1.5 hours following parenteral administration but is minimal systemically when administered sublingually. Clearance may be altered in hepatic impairment, necessitating careful monitoring and dose adjustments in patients with moderate to severe liver disease.

Dosage Forms

Adults

For adults, buprenorphine/naloxone is available as sublingual tablets (e.g., Suboxone and Zubsolv) and as sublingual or buccal films (e.g., Suboxone film, Bunavail). Dosing for induction of opioid dependence treatment typically begins with lower doses administered in divided doses on Day 1, such as up to 4.2 mg buprenorphine and 0.7 mg naloxone for buccal films and up to 5.7 mg/1.4 mg for sublingual tablets. Maintenance doses are usually given as a single daily dose ranging from 8 mg/2 mg to 16 mg/4 mg depending on the formulation. Dose adjustments should be individualized based on patient response and opioid use history.

Adolescents

Safety and efficacy of buprenorphine/naloxone in the pediatric population, including adolescents, have not been adequately established; therefore, use in children and adolescents is not generally recommended without specialized assessment and monitoring. When administered, dosing must be carefully determined by a specialist experienced in managing opioid dependence in younger patients.

Special Populations

In geriatric patients, no specific dosage adjustments have been definitively recommended; however, due to possible decreased hepatic and renal function, cautious dosing and close monitoring are prudent. In patients with moderate liver impairment, lower doses and careful titration may be required due to reduced metabolism and clearance, whereas buprenorphine/naloxone is contraindicated in severe hepatic impairment. No specific dosage recommendations exist for renal impairment, though cautious use is advised given limited renal clearance of active metabolites.

Mechanism Of Action

Buprenorphine is a partial agonist at the mu-opioid receptor, exhibiting high affinity and slow dissociation kinetics that produce a ceiling effect on opioid activity, thereby reducing the risk of respiratory depression relative to full agonists. It also acts as an antagonist at kappa-opioid receptors, which may contribute to its antidepressant and anti-hyperalgesic properties. Naloxone is a competitive opioid receptor antagonist primarily effective at mu-opioid receptors and is included in the combination product to deter intravenous misuse due to its poor sublingual bioavailability but potent receptor blockade when injected.

The combination exploits the pharmacodynamic properties wherein buprenorphine mitigates withdrawal and craving by activating opioid receptors sufficient to prevent withdrawal symptoms but with lower abuse potential. Naloxone remains pharmacologically inactive when administered sublingually due to minimal absorption but precipitates withdrawal if the formulation is misused intravenously, thereby reducing abuse liability. This pharmacological profile supports buprenorphine/naloxone as an effective maintenance therapy for opioid dependence with a safer side effect and abuse profile compared to methadone or full opioid agonists.

Clinically, the partial agonist activity provides analgesic and withdrawal suppression effects, while the antagonist component safeguards against intravenous misuse, contributing to treatment adherence and safety. Research indicates that buprenorphine's interaction with opioid receptors also modulates intracellular signaling pathways differently from full agonists, leading to reduced opioid tolerance and dependence development compared to traditional opioids.

Pharmacological Actions

Partial mu-opioid receptor agonist activity providing opioid agonist effects with ceiling on respiratory depression risk
Kappa-opioid receptor antagonist activity potentially modulating mood and stress responses
Reduction of opioid withdrawal symptoms and craving by opioid receptor partial activation
Naloxone antagonistic activity deterring intravenous misuse and precipitating withdrawal upon parenteral administration
CNS opioid receptor modulation leading to attenuation of opioid dependence
Slower dissociation from opioid receptors prolonging duration of action
Minimal systemic naloxone absorption via sublingual/buccal routes
Decreased opioid tolerance compared to full agonist opioids
Combination therapy reducing potential for misuse and diversion

Therapeutic Clinical Uses

Treatment and maintenance therapy for opioid (narcotic) dependence and addiction
Induction therapy for opioid withdrawal in physically dependent patients
Prevention of opioid withdrawal symptoms during opioid detoxification
Reducing illicit opioid use and supporting opioid abstinence
Part of medication-assisted treatment (MAT) in opioid use disorder management
Use in supervised medical withdrawal programs
Maintenance therapy to reduce risk of opioid overdose and relapse
Facilitation of opioid dependence recovery in outpatient settings
Combination therapy to minimize intravenous abuse potential

Side Or Adverse Effects

Chills and fever-like symptoms
Cough and hoarseness
Dizziness, lightheadedness, and feeling faint
Flushing or redness of the skin
Headache
Lower back or side pain
Painful or difficult urination
Sweating
Agitation and restlessness
Facial or peripheral swelling (edema)
Chest tightness or difficulty breathing
Skin rash, itching, hives (allergic reactions)
Nausea, vomiting, and diarrhea
Muscle tremors or twitching
Sleep disturbances including insomnia
Toothache and serious dental complications
Symptoms of overdose including shallow breathing, pinpoint pupils, confusion, and drowsiness
Rare but serious adrenal insufficiency symptoms such as fatigue and hypotension

Precautions

Monitor patients regularly for effectiveness and potential adverse effects
Avoid use within 14 days of MAOI therapy to prevent hypertensive crisis or serotonin syndrome
Use caution in patients with respiratory disorders like COPD or sleep apnea due to risk of respiratory depression
Use cautiously in patients with liver disease, especially moderate impairment; contraindicated in severe hepatic impairment
Monitor for signs of opioid withdrawal and serotonin syndrome
Advise patients about the risk of neonatal opioid withdrawal syndrome if used during pregnancy
Warn about potential for abuse, habit formation, and diversion
Adjust dose carefully in elderly patients or those with renal or hepatic impairment
Avoid concurrent use with CNS depressants without medical supervision due to enhanced sedation
Advise patients not to operate machinery or drive until effects are known
Ensure secure storage to prevent misuse by others
Monitor dental health due to increased risk of serious tooth problems
Advise gradual tapering before discontinuation to reduce withdrawal symptoms
Be vigilant for signs of adrenal insufficiency and cardiac arrhythmias

Warnings

Risk of respiratory depression and opioid overdose, particularly during initiation or dose escalation
Potential for life-threatening opioid withdrawal precipitated if administered too soon after other opioids or by inappropriate routes
Serious allergic reactions including anaphylaxis can occur
Contraindicated in severe hepatic impairment
May cause sleep-related breathing disorders like sleep apnea that warrant dose adjustment
Simultaneous use with alcohol or other CNS depressants increases CNS depression risk
Risk of QT prolongation and cardiac arrhythmias, especially in patients with preexisting conditions
Pregnancy exposure may lead to neonatal opioid withdrawal syndrome
Abrupt discontinuation may provoke severe withdrawal symptoms
Risk of serotonin syndrome when combined with serotonergic drugs
Potential risk of adrenal insufficiency with prolonged use

Contraindications

Hypersensitivity to buprenorphine, naloxone, or any component of the formulation
Severe hepatic impairment or acute liver disease
Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping such therapy
Patients with respiratory depression or severe bronchial asthma in an unmonitored setting
Known or suspected gastrointestinal obstruction including paralytic ileus
Use in patients with acetylcholinesterase inhibitor use requiring caution due to interaction potentials
Patients who have failed naloxone challenge test when switching from full opioid agonists
Use by individuals with known naloxone sensitivity
Not established for use in pediatric populations for opioid dependence treatment

Drug Interactions

Contraindicated with drugs that prolong QT interval or cause serious cardiac arrhythmias
Potential interactions with CYP3A4 inhibitors or inducers affecting buprenorphine metabolism (e.g., ketoconazole, fluconazole)
Avoid combination with CNS depressants such as benzodiazepines, alcohol, barbiturates, or other opioids due to risk of enhanced sedation and respiratory depression
Avoid concomitant use with opioid antagonists such as naltrexone that may precipitate withdrawal
Careful use with serotonergic agents to prevent serotonin syndrome
Interacts with certain antimicrobials like macrolides, azoles, potentially altering plasma levels
Avoid coadministration with drugs affecting cardiac conduction like amiodarone, sotalol, or quinidine
Interaction with antiretrovirals such as ritonavir affecting drug levels
Interaction with anticonvulsants like carbamazepine may reduce effectiveness
Combining with clonidine or yohimbine may increase side effects like hypotension or sedation
Potential interaction with antidepressants including tricyclics and SSRIs
Drugs that alter gastric pH or motility may affect sublingual absorption

Preparations Of The Drug

Sublingual tablets (e.g., Suboxone, Zubsolv) containing fixed-dose combinations of buprenorphine/naloxone
Sublingual films designed for rapid dissolution and ease of administration (e.g., Suboxone film)
Buccal films (e.g., Bunavail) with specific dosing strengths available
Commercial products available in various dose strengths ranging from approximately 2 mg buprenorphine/0.5 mg naloxone to 16 mg/4 mg
Packaging designed to reduce diversion and misuse, including child-resistant and moisture-resistant materials
Available with patient medication guides and detailed administration instructions
Products may be branded differently with slight formulation variations (e.g., Cassipa, Suboxone, Zubsolv)
Commercially produced formulations have undergone FDA approval for maintenance treatment of opioid dependence
All preparations are prescription-only and regulated due to opioid content